Annual General Meeting 2023

Genmab A/S’ 2023 Annual General Meeting took place on Wednesday, March 29, 2023, at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen V, Denmark.

To replay the webcast of the Annual General Meeting, please use one of the following links:

Webcast (English)

Webcast (Danish)

Please click on the links below for information concerning Genmab A/S’ Annual General Meeting 2023

 Shareholder letter
 Notice of Annual General Meeting 2023 with agenda, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy
 Register online or use the registration form
 Submit proxy or postal vote online or use the form to submit proxy or postal vote
 2022 Annual Report of Genmab A/S
 2022 Compensation Report

The total number of voting rights and total share capital per February 23, 2023, are:
Total Number of Voting Rights: 65,961,573
Total Share Capital: 65,961,573

Questions regarding registration to participate may be directed to Euronext Securities at tel. no. (+45) 43 58 88 66 or [email protected].

Investor inquiries

  • Andrew Carlsen

    Vice President,
    Head of Investor Relations

    Telephone: +45 3377 9558

    Kalvebod Brygge 43
    1560 Copenhagen V

  • We process your personal data in accordance with applicable rules. Please click here to read our Privacy Policy.

    Please note that Genmab A/S, as a general rule, no longer sends the calling to Annual General Meetings by postal mail. If you wish to receive the invitation to future Annual General Meetings via e-mail, please register your e-mail address at the InvestorPortal. If you do not have access to an e-mail address, please contact Euronext Securities at: (+45) 43 58 88 66.

  • Who we are

    Read about Genmab’s purpose, core values and key accomplishments

    Learn more

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

  • Innovation for the future

    We are developing next-generation technologies

    See our technologies

You are now leaving to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.